CRISPR/Cas13 Antiviral Platform
Broad-spectrum RNA virus infections (e.g., Coronaviruses)
Pre-clinicalActive
Key Facts
Indication
Broad-spectrum RNA virus infections (e.g., Coronaviruses)
Phase
Pre-clinical
Status
Active
Company
About Avocet Bio
Avocet Bio is a private, preclinical-stage biotech developing a CRISPR/Cas13-based platform for broad-spectrum antiviral therapeutics. Founded by a team of clinician-scientists and seasoned drug developers, the company aims to create a 'plug-and-act' solution capable of rapidly addressing diverse RNA virus threats, including potential future pandemics. While still in early development, its technology platform represents a novel approach in the infectious disease space, targeting the viral RNA genome and transcripts to block proliferation. The company is pre-revenue and focused on advancing its platform technology.
View full company profile